Reversal of chronic rejection after treatment failure with FK506 and RS61443.
Roberts
J P
JP
Lake
J R
JR
Hebert
M
M
Nikolai
B
B
Ascher
N L
NL
Ferrell
L D
LD
D000328:Adult; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000601:surgery; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy* / Q000473:pathology; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008103:Liver Cirrhosis / Q000150:complications / Q000601:surgery; D008111:Liver Function Tests; D008113:Liver Neoplasms / Q000150:complications / Q000601:surgery; D016031:Liver Transplantation / Q000276:immunology* / Q000473:pathology; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016572:Cyclosporine; D009173:Mycophenolic Acid; D016559:Tacrolimus